45. Retinopathy after tilorone hydrochloride.
Weiss JN, Ochs AL, Abedi S, Selhorst JB.
Two patients, a 34-year-old woman and a 50-year-old woman, received tilorone
HCl, an experimental antitumor drug.
After taking the drug orally (total dose, 152 g), the first patient developed
corneal subepithelial infiltrates and toxic retinopathy characterized by fine pigment
舒从 于 亟仄舒亠亠, mottling of the peripheral fundus and macula with mild arteriolar narrowing.
仂仗舒仆仂 仄亳从亳仆舒 Although visual acuity was 6/6 (20/20) throughout treatment, Goldmann perimetry
showed marked peripheral constriction of the visual fields and results of an
(亳仍仂仂仆舒) 亟仍 亰亟仂仂于 electroretinogram and an electro-oculogram were abnormal. After taking the
于舒亳 亞仍舒亰 仄仂亢仆仂 drug orally (total dose, 189 g), the second patient developed corneal subepithelial
亳舒 亟仂从舒亰舒仆仆仂亶? infiltrates, severe bilateral arteriolar narrowing, and mild pigment mottling of the
macula.
ERG and EOG were moderately attenuated. Visual fields by Goldman perimetry
were within normal limits. Tilorone HCl, like chloroquine, may be an antioxidant
that affects the free radical scavenging mechanism of the retinal pigment
epithelium. Extensive testing should be done on all patients taking tilorone HCl in
order to detect the initial manifestations of retinopathy.